SCHEMBL5204850

SCHEMBL5204850

COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(Br)cn4)c(C)c3C)c2cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 10/20 0.55
MAPT P10636 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
PDGFRA P16234 7/20 0.52
KDR P35968 6/20 0.52
KIT P10721 2/20 0.52
RIPK2 O43353 1/20 0.52
STK10 O94804 1/20 0.52
ABL1 P00519 1/20 0.52
LCK P06239 1/20 0.52
LYN P07948 1/20 0.52
RET P07949 1/20 0.52
PDGFRB P09619 1/20 0.52
BCR P11274 1/20 0.52
FGFR1 P11362 1/20 0.52
SRC P12931 1/20 0.52
FLT1 P17948 1/20 0.52
MAPK3 P27361 1/20 0.52
HTR2A P28223 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205681 0.91 MET (0.56) METMEN1KMT2APDGFRAKDR
SCHEMBL5206112 0.89 KDR (0.57) METPDGFRAKDRKITRIPK2
SCHEMBL5204982 0.86 PDGFRA (0.51) METPDGFRAKDRKITRIPK2
SCHEMBL5203378 0.86 KDR (0.57) METPDGFRAKDRKITRIPK2
SCHEMBL5205557 0.84 KDR (0.71) METPDGFRAKDRKITRIPK2
SCHEMBL5203290 0.83 PDGFRA (0.70) METPDGFRAKDRKITSRC
SCHEMBL5201618 0.83 NPC1 (0.54) METMAPTPDGFRAKDRKIT
SCHEMBL5205605 0.82 PDGFRA (0.72) METPDGFRAKDRKITLCK
SCHEMBL7838062 0.81 KDR (0.52) METPDGFRAKDRKITRIPK2
SCHEMBL5202707 0.81 PDGFRA (0.76) PDGFRAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS MET 2097/4885MAPT 4850/4885MEN1 2544/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 MET 2063/4885MAPT 4796/4885MEN1 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.